Pfizer CEO: ‘No reason’ we can’t do an inversion deal, Treasury rules or no

Tracy Staton Pfizer CEO Ian Read makes no apologies for his interest in working a deal to move his tax home overseas. Despite the U.S. government's attempt to discourage tax inversions–like ...

Big Pharma backs EU antibiotic R&D plan, Pfizer prompts Karo cuts, Advent closes £146M fund

Nick Paul Taylor In this week's EuroBiotech Report, a who's who of Big Pharma companies joined a European public-private consortium to develop and test new economic models of ...

Pfizer turns back Mylan’s patent challenge to Sutent

Eric Palmer Pfizer execs can sigh with relief now that a federal court has backed the company's patents on kidney cancer drug Sutent. The med has become increasingly important to ...

Will Pfizer rebid for AstraZeneca? Keep an eye on U.S. midterm election for clues

Tracy Staton Will Pfizer come back at AstraZeneca? That's been the question of the summer, especially since the U.S. Treasury Department rolled out new rules for tax-inversion deals. FiercePharma ...

Pfizer, Ranbaxy prevail in antitrust fight over Lipitor generics

Tracy Staton Pfizer and Ranbaxy Laboratories persuaded a U.S. judge to toss out an antitrust lawsuit accusing them of conspiring to delay generic versions of the cholesterol-fighting ...

Pfizer, Merck, pick up hefty vax sales bump with CDC nod in seniors

Carly Helfand Pfizer's Prevnar 13, the world's best-selling vaccine, scored a big win Wednesday, nabbing a CDC committee nod for universal use in adults over the age of 65. ...

Pfizer joins crowd of companies snapping up sterile injectable players

Eric Palmer Pfizer said Wednesday that it would buy New Jersey-based InnoPharma, for $ 225 million in cash and up to $ 135 million in contingent milestone payments. FiercePharma News

Pfizer amps up its ‘Get old’ campaign with more content, more social media

Tracy Staton What's #FOGO? Hint: Many of us have it. Another hint: Pfizer wants people to talk about it. FiercePharma News

Judge tosses decade-old investor suit against Pfizer and Celebrex weeks before trial

Eric Palmer A long-running and often contentious securities lawsuit tied to Pfizer's vilified pain drugs Celebrex and Bextra was set for a September trial, ...

Pfizer yanks 220,000 Pristiq bottles on pill mix-up

Tracy Staton For the second time in recent months, Pfizer is recalling hundreds of thousands of bottles of a drug when one was found to contain the wrong tablet. FiercePharma News

Another Pfizer bid for AstraZeneca? Investors weigh in

Stacy Lawrence A higher price could get a deal done between Pfizer and AstraZeneca if British regulators play along, but investors aren't convinced that would be a particularly ...

With Shire takeover bid, AbbVie looks to succeed where Pfizer failed

Carly Helfand AbbVie may be working with some of the same advisers who worked on Pfizer's so-far-failed play for AstraZeneca. But after three rejections from target Shire–the ...
Page 4 of 11« First...23456...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS